Expression and Preliminary Research on the Soluble Domain of EV-D68 3A Protein.
- Author:
Ting LI
;
Jia KONG
;
Xiao-fang YU
;
Xue HAN
- Publication Type:Journal Article
- MeSH:
Amino Acid Sequence;
Enterovirus D, Human;
chemistry;
genetics;
metabolism;
Escherichia coli;
genetics;
metabolism;
Gene Expression;
Models, Molecular;
Molecular Sequence Data;
Protein Structure, Tertiary;
Sequence Alignment;
Viral Proteins;
chemistry;
genetics;
metabolism
- From:
Chinese Journal of Virology
2015;31(6):653-659
- CountryChina
- Language:Chinese
-
Abstract:
To understand the structure of the soluble region of Enterovirus 68 3A protein, we construct a prokaryotic expression vector expressing the soluble region of EV-D68 3A protein, and identify the forms of expression product after purification. The EV-D68 3A(1-61) gene was amplified by PCR and then cloned into the expression vector pET-28a-His-SUMO. The recombinant plasmid was transformed into Escherichia coli BL21 induced by IPTG to express the fusion protein His-SUMO-3A(1-61). The recombinant protein was purified by Ni-NTA Agarose and cleaved by ULP Protease to remove His-SUMO tag. After that, the target protein 3A(1-61) was purified by a series of purification methods such as Ni-NTA, anion exchange chromatography and gel filtration chromato- graphy. Chemical cross-linking reaction assay was taken to determine the multiple polymerization state of the 3A soluble region. A prokaryotic expression vector pET28a-His-SUMO-3A(1-61) expressing the solution region of EV-D68 3A was successfully constructed and plenty of highly pure target proteins were obtained by multiple purification steps . The total protein amount was about 5 mg obtained from 1L Escherichia coli BL21 with purity > 95%. At the same time, those results determined the homomultimer form of soluble 3A construct. These data demonstrated that the expression and purification system of the soluble region of 3A were successfully set up and provide some basic konwledge for the research about 3A crystal structure and the development of antiviral drugs targeted at 3A to block viral replication.
